NCT05294172View on ClinicalTrials.gov

KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

295

Participants

Timeline

Start Date

June 7, 2022

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Nasopharyngeal CarcinomaRecurrent or Metastatic
Interventions
DRUG

KL-A167

KL-A167 4-6 cycles for combined therapy.KL-A167 maintenance.

DRUG

Gemcitabine

4-6 cycles for combined therapy

DRUG

Cisplatin

4-6 cycles for combined therapy.

DRUG

Placebo

4-6 cycles for combined therapy.Placebo maintenance.

Trial Locations (1)

100021

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors
lead

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

INDUSTRY